Karyopharm Therapeutics Inc
KPTI5.410USD
-0.320-5.58%
收盤 09/19, 16:00（美東）報價延遲15分鐘
46.78M總市值
虧損本益比TTM
關於 Karyopharm Therapeutics Inc 公司
Karyopharm Therapeutics Inc. 是一家商業階段製藥公司。該公司致力於發現、開發和商業化針對核輸出的藥物，用於治療癌症和其他疾病。該公司正在開發和商業化小分子選擇性核輸出抑制劑 (SINE) 化合物，該化合物可抑制核輸出蛋白輸出蛋白 1 (XPO1)。其主要資產 XPOVIO (selinexor) 與硼替佐米和地塞米松聯合用於治療已接受過至少一種先前治療的多發性骨髓瘤成人患者。該公司正在評估 selinexor 在某些血液和實體腫瘤惡性腫瘤中的應用，包括多發性骨髓瘤、子宮內膜癌、蕈樣肉芽腫 (MF) 和瀰漫性大 B 細胞淋巴瘤 (DLBCL)。該公司的候選產品 eltanexor 是一種口服 SINE 化合物，與 selinexor 一樣，可選擇性阻斷核輸出蛋白 XPO1。
公司簡介
公司代碼KPTI
公司名稱Karyopharm Therapeutics Inc
上市日期Nov 06, 2013
CEOMr. Richard A. Paulson
員工數量279
證券類型Ordinary Share
年結日Nov 06
公司地址85 Wells Avenue
城市NEWTON
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02459
電話16176580600
網址https://karyopharm.com/
公司代碼KPTI
上市日期Nov 06, 2013
CEOMr. Richard A. Paulson
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
12.28K
+3.18%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.61K
+6.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Mr. Chen Schor, CPA
Mr. Chen Schor, CPA
Independent Director
Independent Director
--
--
Mr. Richard A. Paulson
Mr. Richard A. Paulson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Brendan Strong
Mr. Brendan Strong
Senior Vice President - Investor Relations and Corporate Communications
Senior Vice President - Investor Relations and Corporate Communications
--
--
Ms. Lori Macomber, CPA
Ms. Lori Macomber, CPA
Executive Vice President, Chief Financial Officer, Treasurer
Executive Vice President, Chief Financial Officer, Treasurer
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Michael Mano, J.D.
Mr. Michael Mano, J.D.
Senior Vice President, General Counsel, Secretary
Senior Vice President, General Counsel, Secretary
12.28K
+3.18%
Mr. Stuart Poulton
Mr. Stuart Poulton
Executive Vice President, Chief Development Officer
Executive Vice President, Chief Development Officer
8.61K
+6.00%
Dr. Reshma Rangwala, M.D., Ph.D.
Dr. Reshma Rangwala, M.D., Ph.D.
Executive Vice President, Chief Medical Officer
Executive Vice President, Chief Medical Officer
7.24K
+8.01%
Mr. Barry E. Greene
Mr. Barry E. Greene
Lead Independent Director
Lead Independent Director
907.00
--
Ms. Sohanya Cheng
Ms. Sohanya Cheng
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
--
--
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月19日 週二
更新時間: 8月19日 週二
持股股東
股東類型
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
8.40%
The Vanguard Group, Inc.
5.98%
J. Wood Capital Advisors LLC
5.28%
Adage Capital Management, L.P.
4.86%
Eversept Partners, LP
2.97%
其他
72.51%
持股股東
持股股東
佔比
T. Rowe Price Investment Management, Inc.
8.40%
The Vanguard Group, Inc.
5.98%
J. Wood Capital Advisors LLC
5.28%
Adage Capital Management, L.P.
4.86%
Eversept Partners, LP
2.97%
其他
72.51%
股東類型
持股股東
佔比
Investment Advisor
20.86%
Hedge Fund
16.35%
Research Firm
7.96%
Corporation
5.28%
Investment Advisor/Hedge Fund
4.11%
Venture Capital
1.83%
Individual Investor
1.14%
Bank and Trust
0.03%
其他
42.45%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
284
4.20M
48.66%
-1.75M
2025Q1
308
4.25M
49.43%
-1.53M
2024Q4
324
4.68M
55.67%
-1.51M
2024Q3
341
4.98M
60.06%
-2.16M
2024Q2
356
5.56M
67.54%
-2.08M
2024Q1
352
5.60M
72.46%
-1.99M
2023Q4
354
5.60M
73.31%
-2.02M
2023Q3
365
5.88M
77.33%
-1.69M
2023Q2
380
6.19M
81.48%
-2.04M
2023Q1
395
6.56M
86.55%
-1.62M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
T. Rowe Price Investment Management, Inc.
139.65K
1.62%
+139.65K
--
Mar 31, 2025
The Vanguard Group, Inc.
510.29K
5.91%
-5.00
-0.00%
Mar 31, 2025
J. Wood Capital Advisors LLC
458.13K
5.3%
--
--
Apr 10, 2025
Adage Capital Management, L.P.
421.32K
4.88%
-1.00
-0.00%
Mar 31, 2025
Eversept Partners, LP
257.15K
2.98%
+117.90K
+84.67%
Mar 31, 2025
J.P. Morgan Securities LLC
147.42K
1.71%
+129.01K
+700.61%
Mar 31, 2025
Citadel Advisors LLC
206.91K
2.39%
-2.00
-0.00%
Mar 31, 2025
Palo Alto Investors LP
324.03K
3.75%
-3.10K
-0.95%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
188.02K
2.18%
-1.00K
-0.53%
Mar 31, 2025
BofA Global Research (US)
132.91K
1.54%
+122.13K
+1132.80%
Mar 31, 2025
查看更多
持股ETF
機構名稱
佔比
暫無數據
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
公告日期
類型
比率
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
Feb 24, 2025
Merger
15→1
